Umida Group publicerade den 14 november 2024 bolagets delårsrapport för det tredje kvartalet år 2024...
Även om Cell Impacts utveckling går långsammare än vi tidigare prognostiserat bedömer vi att affärsi...
Redeye has an overall positive impression from the visit to the Hudiksvall factory.
Net sales and EBIT were in line with our estimates.
We lift '24e EBITDA by 27%, '25-'26e up 9-4% Doro now closer to a done deal, could lift '28e EBITA ~...
Redeye comments on Nekkar’s Q3 report that missed our expectations, mainly driven by a lower sales a...
Xplora Technologies AS has made a move to acquire Doro AB, offering a 38% premium to shareholders.
Redeye is again positively surprised to see CTEK beating our estimates on the top line and profitabi...
Redeye comments on Raketech’s Q3-results which were weaker than expected, driven mainly by Sub-affil...
Signs SEK 132m expansion order from Swedish Space Corporation New run-rate of ~SEK 250m is 37% above...
Redeye comments on Thunderful Group’s Q3’24 report, which was weaker than expected, primarily due to...
Redeye provides its initial take on Surgical Science’s Q3 2024 report, which beat our expectations.
Redeye is encouraged by the new management in Sivers, guiding for a long-term ambition of reaching a...
Redeye comments on Better Collective’s Q3-results which were in line with the preliminary announceme...
Redeye somewhat cuts its forecasts and Base Case following a Q3 with soft ARR growth yet lower OPEX ...
